Pliant Therapeutics, Inc. PLRX
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -51.22%
- 1 year
- -61.85%
5D -0.1200 (-16.22%)
- Market cap
- 36.89M
- EPS (ttm)
- -1.46
- Shares out
- 60.85M
- Forward P/E
- -3.32
- YTD return
- -51.22%
- 1-year return
- -61.85%
- 50-day average
- 14.08
- 200-day average
- 13.14
- Volume
- 933.40K
- Avg volume
- 402.23K
- Open
- 0.6001
- Previous close
- 0.62
- Day's range
- 0.5719 – 0.6139
- 52-week range
- 0.5951 – 1.61
- Beta
- 1.09
- Price target
- 40.18 (+6652.1%)
Key statistics
- Enterprise value
- 459.58M
- Price / book
- 2.35
- Free cash flow
- -84.08M
- Total cash
- 404.51M
- Total debt
- 60.21M
- Return on equity
- -47.52%
- Short % of float
- 12.16%
Fundamental scorecard
5 of 25 checks passed on PLRX’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.99 | -0.95 | +0.04 | +4.04% |
| Aug 7, 2024 | Jun 1, 2024 | -0.85 | -0.92 | -0.07 | -8.24% |
| Aug 7, 2024 | Jun 1, 2024 | -0.85 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.76 | -0.78 | -0.02 | -2.63% |
| May 6, 2024 | Mar 1, 2024 | -0.76 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 8, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 8, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 8, 2024 | Needham | reit | Buy | Buy |
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pliantrx.com
News
Your note
Sign in to keep a note on PLRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEUNG LILY | Officer | Stock Award(Grant) | Jan 22, 2024 | 26,795 |
| COULIE BERNARD J | Chief Executive Officer | Sale | Jul 9, 2024 | 892,253 |
| CUMMINGS KEITH LAMONT | Chief Financial Officer | Sale | Jul 9, 2024 | 282,115 |
| HULL JOHANNES P. | Officer | Sale | Jul 9, 2024 | 259,285 |
| LEFEBVRE ERIC | Officer | Sale | Jul 9, 2024 | 213,052 |
| OUIMETTE MICHAEL | General Counsel | Sale | Jul 9, 2024 | 94,044 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 9.81% | 5,972,257 | 79.67M | Sep 29, 2024 |
| Blackrock Inc. | 8.58% | 5,218,965 | 69.62M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 7.94% | 4,834,813 | 64.50M | Sep 29, 2024 |
| FMR, LLC | 6.41% | 3,899,481 | 52.02M | Sep 29, 2024 |
| Vanguard Group Inc | 5.80% | 3,526,514 | 47.04M | Sep 29, 2024 |
| Redmile Group, LLC | 5.25% | 3,197,491 | 42.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 3.97% | 2,414,413 | 32.21M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.34% | 2,030,496 | 27.09M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.40% | 1,462,592 | 19.51M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 2.18% | 1,324,096 | 17.66M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.44% | 873,606 | 11.65M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.95% | 579,914 | 7.74M | Aug 30, 2024 |
